Pharmacokinetics of tildipirosin in beagle dogs.
Abstract
The objective of this study was to investigate the pharmacokinetic profile of tildipirosin (TD) in 24 beagle dogs following intravenous (i.v.) and intramuscular (i.m.) administration, respectively, at 2, 4, and 6?mg/kg. Plasma samples at certain time points (0-14?days) were collected, and the concentrations of drug were quantified by UPLC-MS/MS. Plasma concentration-time data and relevant parameters were described by noncompartmental through WinNonlin 6.4 software. After single i.m. injection at 2, 4, and 6?mg/kg body weight, mean maximum concentration (Cmax ) was 412.73?±?76.01, 1,051?±?323, and 1,061?±?352?ng/ml, respectively. Mean time to reach Cmax was 0.36?±?0.2, 0.08?±?0.00, and 0.13?±?0.07?hr after i.m. injection at 2, 4, and 6?mg/kg, respectively. The mean value of T1/2λz for i.m. administration at doses of 2, 4, and 6?mg/kg was 71.39?±?28.42, 91 .33?±?50.02, and 96.43?±?45.02?hr, respectively. The mean residence times were 63.81?±?10.96, 35.83?±?15.13, and 38.18?±?16.77?hr for doses of 2, 4, and 6?mg/kg, respectively. These pharmacokinetic characteristics after i.m. administration indicated that TD could be rapidly distributed into tissues on account of the high lipid solubility and then released into plasma. In addition, the absolute bioavailability of 2?mg/kg after i.m. injection was 112%. No adverse effects were observed after i.v. and i.m. administration.